FDA approves first drug for hallucinations and delusions associated with PD

On April 29, the U.S. the Food and Drug Administration (FDA) approved Nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s disease. Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here